Sort   by:  
 Page size 
MetabolomicsMulti-omics characterization of acquired Olaparib resistance in BRCA1 and BRCA2 mutant breast cancer cell lines
Poly (ADP-ribose) polymerase inhibitors (PARPi) are widely used as targeted therapies against breast cancers with BRCA mutations. However, the development of resistance to PARPi poses a significant challenge for long-term efficacy of these therapies, warranting further understanding of mechanisms of...
2026-05-11 | MTBLS12109 | MetaboLights
MetabolomicsTargeting SLC1A5-mediated glutamine metabolism overcomes PARP inhibitor resistance in ovarian cancer

Poly(ADP-ribose) polymerase inhibitors (PARPi), such as olaparib, have significantly improved outcomes in ovarian cancer (OC); however, therapy resistance remains a major clinical challenge. Here, we showed that glutamine metabolism was upregulated in PARPi-resistant OC cells and identified the g...

2026-04-08 | MTBLS14072 | MetaboLights
ProteomicsMulti-omics characterization of acquired Olaparib resistance in BRCA1 and BRCA2 mutant breast cancer cell lines
Poly (ADP-ribose) polymerase inhibitors (PARPi) are widely used as targeted therapies against breast cancers with BRCA mutations. However, the development of resistance to PARPi poses a significant challenge for these therapies, warranting further need for mechanistic insight into PARPi resitance. H...
ORGANISM(S): Homo sapiens (Human) 
2025-08-25 | PXD060950 | Pride
Phosphoproteomics Brca1/2 mutations Ethcd Adp-ribosylation Proteomics Dna damage Parp inhibitors Lc-msms Olaparib resistance 
ProteomicsMulti-omics characterization of acquired Olaparib resistance in BRCA1 and BRCA2 mutant breast cancer cell lines
This is part 2 of the same project. Part 1 was just uploaded with the reference: 1-20250110-174238-3123982. Please merge if possible! Poly (ADP-ribose) polymerase inhibitors (PARPi) are widely used as targeted therapies against breast cancers with BRCA mutations. However, the development of resistan...
ORGANISM(S): Homo sapiens (Human) 
2025-08-25 | PXD060046 | Pride
Phosphoproteomics Brca1/2 mutations Ethcd Adp-ribosylation Proteomics Dna damage Parp inhibitors Lc-msms Olaparib resistance 
GenomicsOlaparib
Olaparib
PRJEB6685 | ENA
GenomicsOlaparib resistance and cisplatin responses in triple negative breast cancer
Olaparib resistance and cisplatin responses in triple negative breast cancer
PRJNA698566 | ENA
GenomicsTranscriptome Analysis of Gene Expression involving C/EBPβ and Olaparib Resistance
Transcriptome Analysis of Gene Expression involving C/EBPβ and Olaparib Resistance
PRJNA644373 | ENA
TranscriptomicsTranscriptomic data of PC WT cell lines (LNCaP, C4-2B and DU145) compared to PC acquired olaparib-resistance (OR) cell lines
PARP inhibitors (PARPi) resistance is not well understood in prostate cancer (PC). The aim of the study was to identify new resistance mechanisms in PC by developing acquired olaparib-resistance PC cell lines.
ORGANISM(S): Homo sapiens 
2022-08-12 | E-MTAB-11989 | biostudies-arrayexpress
GenomicsTranscriptomic analysis of acquired olaparib resistance in a high-grade serous ovarian cancer PDX model
Transcriptomic analysis of acquired olaparib resistance in a high-grade serous ovarian cancer PDX model
PRJNA1508690 | ENA
TranscriptomicsOlaparib resistance and cisplatin responses in triple negative breast cancer
PARP inhibitor and platinum based drugs such as cisplatin are promising therapies for triple negative breast cancer and exploit the deficiencies in BRCA1 or BRCA2, or homologous recombination repair defects. However, PARP inhibitor resistance is proven to be a major clinical problem. Acquired PARP i...
ORGANISM(S): Homo sapiens 
2021-07-22 | GSE165914 | GEO
Sort   by:  
 Page size